Immutep Ltd 2024 AR2
The report highlights Immutep Limited's progress in the 2024 financial year as a leading biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune diseases. Key achievements include advancing its lead product candidate, eftilagimod alfa (efti), towards a Phase III trial in non-small cell lung cancer in collaboration with MSD, and initiating clinical trials for its autoimmune candidate, IMP761. Financially, the company secured A$100.2 million in new equity, extending its cash runway to the end of 2026. Immutep also expanded its intellectual property portfolio with ten new patents and scaled up its manufacturing process to commercial levels.
Company: Immutep Ltd
Sector: Professional & technical services
Country: Australia
Year: 2024
Type: AR2
Pages: 84
Back to company
Immutep Ltd
Annual Report
The report highlights Immutep Limited's progress in the 2024 financial year as a leading biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune diseases. Key achievements include advancing its lead product candidate, eftilagimod alfa (efti), towards a Phase III trial in non-small cell lung cancer in collaboration with MSD, and initiating clinical trials for its autoimmune candidate, IMP761. Financially, the company secured A$100.2 million in new equity, extending its cash runway to the end of 2026. Immutep also expanded its intellectual property portfolio with ten new patents and scaled up its manufacturing process to commercial levels.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available